WT4869 / Sumitomo Pharma - LARVOL DELTA

PHASE 1/2 STUDY OF DSP-7888 IN PATIENTS WITH HIGHER-RISK (HR) MYELODYSPLASTIC SYNDROMES (MDS) AFTER FAILURE OF AZACITIDINE (AZA) THERAPY (EHA 2019) - P1/2; "Of the 42 patients, 37 were evaluable for WT1 reactive immune response and the results are shown in the Table.Conclusion DSP-7888 was tolerable and showed signs of clinical activity in patients with HR-MDS; those who had a positive immune response showed a significantly longer OS than those who were negative. Identifying the optimal population for treatment with DSP-7888 is important for further investigations."

Clinical • P1/2 data • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Neutropenia • Oncology • Renal Cell Carcinoma